Lilly Drug to Undergo Alzheimer's Clinical Trial
Posted on: Thursday, 15 June 2006, 18:00 CDT
By Jeff Swiatek, The Indianapolis Star
Jun. 15--Eli Lilly's popular osteoporosis drug Evista will be tested to see if it slows the progress of Alzheimer's dementia in women.
If successful, the drug could fill a huge need. Currently, no approved drugs are on the market to reverse the ravages of Alzheimer's or stop it from progressing, although four drugs are approved to treat the disease's symptoms.
Lilly and several other drug makers are testing numerous compounds to try to find ways to fight the disease.
There are intriguing reasons to believe Evista, which was Lilly's fourth-best-selling drug last year, might work against Alzheimer's, a progressive disease that gradually robs patients of their memories and thinking abilities.
In 2001, researchers at Lilly and the University of California released results of a review of 7,705 women over 70 that showed those who had taken Evista did better on tests of memory and attention than those who took a placebo.
The new one-year trial will enroll 72 women who are diagnosed with Alzheimer's at the Indiana University School of Medicine in Indianapolis and at Stanford University in California.
It's the first Alzheimer's efficacy study with the Lilly drug in a tightly controlled clinical trial with patients, said Dr. Martin R. Farlow, a neurology professor at the IU School of Medicine.
"There is a pretty good prospect the drug really does work" against Alzheimer's, Farlow said. "It would be a nice thing to prove."
The new study is funded by the National Institutes of Health. Lilly will supply the Evista pills, but otherwise is not part of the trial, Farlow said.
Lilly also is seeking Food and Drug Administration approval to market Evista to prevent breast cancer. Lilly would need more than one study to win FDA approval to sell the drug for Alzheimer's, Farlow said.
Evista has been on the market since 1998.
-----
To see more of The Indianapolis Star, or to subscribe to the newspaper, go to http://www.IndyStar.com.
Copyright (c) 2006, The Indianapolis Star
Distributed by Knight Ridder/Tribune Business News.
For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
LLY,
Source: The Indianapolis Star
Related Articles
- Mithridion Announces Progress With Drugs for Alzheimer's Disease and Schizophrenia
- Beijing International Studies University Adopts SoftBrands Hospitality Solution as Core Curriculum
- Viral Genetics Reports Initial Findings From Lyme Disease Study
- Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study
- Abdominal Fat Distribution Predicts Heart Disease: Study
- Eli Lilly and Company Submits New Drug Application for EVISTA for Reduction of Invasive Breast Cancer Risk in Postmenopausal Women
- Medivation's Dimebon Meets All Five Efficacy Endpoints in Phase 2 Alzheimer's Disease Study; Conference Call Begins at 1:00 P.M. Eastern Time Today
- Almost All New Drug Approvals Receive FDA Requests for Post-Marketing Studies
- Green Tea Ingredient Protects Brain Against Alzheimer's Disease: Study
- Novartis drug aids bones in Paget's disease-study
 |
 |
User Comments (0)
RSS Feeds